cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Neurocrine Biosciences Inc
26 own
13 watching
Current Price
$0
$1.95
(1.81%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
10,378.8M
52-Week High
52-Week High
129.29
52-Week Low
52-Week Low
75.25
Average Volume
Average Volume
0.41M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
20.4735
iconMarket Capitalization10,378.8M
icon52-Week High129.29
icon52-Week Low75.25
iconAverage Volume0.41M
iconDividend Yield--
iconP/E Ratio20.4735
What does the Neurocrine Biosciences Inc do?
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Read More
How much money does Neurocrine Biosciences Inc make?
News & Events about Neurocrine Biosciences Inc.
Globe Newswire
25days ago
- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-...
Zolmax
26days ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX Get Rating) Director Stephen A. Sherwin sold 30,000 shares of the firms stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $118.86, for a total value of $3,565,800.00. Following the completion of the transaction, the ...
Ticker Report
1month ago
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX Get Rating) have earned an average rating of Moderate Buy from the twenty analysts that are presently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation, ...
ETF Channel
1month ago
Symbols mentioned in this story: MDYG, STLD, NBIX, TTC Exchange traded funds (ETFs) trade just like stocks, but instead of shares investors are actually buying and selling units. These units can be traded back and forth just like stocks, ...
Frequently Asked Questions
Frequently Asked Questions
What is Neurocrine Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Neurocrine Biosciences Inc shares?
plus_minus_icon
How can I buy Neurocrine Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Neurocrine Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Neurocrine Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Neurocrine Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Neurocrine Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Neurocrine Biosciences Inc?
plus_minus_icon
What percentage is Neurocrine Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Neurocrine Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$1.95
(1.81%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
LivaNova PLC
LivaNova PLC
$58.79
$0.74 (1.27 %)
NovoCure Limited
NovoCure Limited
$94.97
$-0.12 (-0.13 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$476.82
$0.00 (0.00 %)
Horizon Therapeutics Public Ltd Co
Horizon Therapeutics Public Ltd Co
$110.06
$0.27 (0.25 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
LivaNova PLC
LivaNova PLC
$58.79
$0.74 (1.27 %)
NovoCure Limited
NovoCure Limited
$94.97
$-0.12 (-0.13 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$476.82
$0.00 (0.00 %)
Horizon Therapeutics Public Ltd Co
Horizon Therapeutics Public Ltd Co
$110.06
$0.27 (0.25 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00